Interferon therapy in alpha and Delta variants of SARS-CoV-2: The dichotomy between laboratory success and clinical realities

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Cytokine Pub Date : 2025-02-01 DOI:10.1016/j.cyto.2024.156829

Atefe Alirezaee , Milad Mirmoghtadaei , Hanieh Heydarlou , Asiye Akbarian , Zahra Alizadeh

引用次数: 0

Abstract

The COVID-19 pandemic has caused significant morbidity and mortality worldwide. The emergence of the Alpha and Delta variants of SARS-CoV-2 has led to a renewed interest in using interferon therapy as a potential treatment option. Interferons are a group of signaling proteins produced by host cells in response to viral infections. They play a critical role in the innate immune response to viral infections by inducing an antiviral state in infected and neighboring cells. Interferon therapy has shown promise as a potential treatment option for COVID-19. In this review paper, we review the current knowledge regarding interferon therapy in the context of the Alpha and Delta variants of SARS-CoV-2 and discuss the challenges that must be overcome to translate laboratory findings into effective clinical treatments.

Abstract Image

查看原文本刊更多论文

干扰素治疗SARS-CoV-2 α和δ变体：实验室成功与临床现实之间的二分法

COVID-19大流行在世界范围内造成了严重的发病率和死亡率。SARS-CoV-2的α和δ变体的出现重新引起了人们对使用干扰素治疗作为潜在治疗选择的兴趣。干扰素是宿主细胞对病毒感染产生的一组信号蛋白。它们通过在被感染细胞和邻近细胞中诱导抗病毒状态，在对病毒感染的先天免疫反应中发挥关键作用。干扰素治疗已显示出作为COVID-19潜在治疗选择的希望。在这篇综述文章中，我们回顾了目前在SARS-CoV-2 α和δ变体背景下有关干扰素治疗的知识，并讨论了将实验室发现转化为有效临床治疗必须克服的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.